Stocks and Investing
Stocks and Investing
Fri, November 5, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Jason Butler Maintained (VRDN) at Buy with Decreased Target to $36 on, Nov 5th, 2021
Jason Butler of JMP Securities, Maintained "Viridian Therapeutics, Inc." (VRDN) at Buy with Decreased Target from $44 to $36 on, Nov 5th, 2021.
Jason has made no other calls on VRDN in the last 4 months.
There is 1 other peer that has a rating on VRDN. Out of the 1 peers that are also analyzing VRDN, 0 agree with Jason's Rating of Hold.
This is the rating of the analyst that currently disagrees with Jason
- Maneka Mirchandaney of "Evercore ISI Group" Initiated at Buy and Held Target at $40 on, Tuesday, October 12th, 2021
Contributing Sources